Four major urology societies agree on diagnosis basics but split on when to treat and what works—mostly because the evidence is thin.
Journal: BJU International | Published: 2026-03-08 | Type: Review | PMID:41795618Authors: Chierigo F, Fallara G, Tozzi M, Salonia A, Ferro M, Alnajjar HM, Muneer A, Pang KH (University of Milan; University College London)
Funding/COI: Not listed
Summary
This review compares Peyronie's disease management guidelines from the AUA, EAU, CUA, and ISSM, mapping where the four panels agree and where they diverge. The short version: everyone agrees on the diagnosis framework and surgical principles; almost nobody agrees on non-surgical treatment, because the evidence for most of it is weak. North American guidelines (AUA, CUA) tolerate a wider range of oral and intralesional therapies than the EAU and ISSM, which largely restrict conservative treatment to clinical trials.
Claims
Spontaneous improvement of penile deformity is uncommon, occurring in fewer than 10–15% of patients during the active phase; curvature progresses in approximately 50%
All four guidelines recognize intracavernosal injection (ICI) with objective curvature measurement as the gold standard before any invasive intervention
Most treatments achieve only 10–20° of curvature improvement
Disease stability criteria vary across panels before surgery is offered: AUA requires >12 months from symptom onset, EAU requires >9–12 months, CUA and ISSM require >6–12 months
Oral medications are not recommended by any guideline as efficacious; intralesional injections are endorsed by all four as a potential non-surgical option, particularly in the acute phase
Penile prosthesis implantation (IPP) is the preferred surgical option across all guidelines for patients with erectile dysfunction unresponsive to medical therapy
Collagenase (Xiaflex/CCH) is unavailable in the EU, which materially shapes divergence between North American and European recommendations
Genetic studies have implicated dysregulation across extracellular matrix remodelling (MMP2, MMP9, COL1A1), profibrotic signalling (TGFB1, SMAD7), and immune mediators as contributors to PD pathogenesis
Study Quality
This is a narrative comparative review, not a systematic review with pooled outcomes. Two authors independently abstracted data from four guidelines into structured tables and classified recommendations as "recommended," "may consider," "unclear benefits," "recommended against," or "not addressed." That framework is reasonable for this type of work, but the authors acknowledge that where explicit recommendations were absent, they inferred panel positions "from contextual discussion"—a soft move that introduces interpretive risk.
The comparison is limited to English-language guidelines from four societies; the APSSM consensus was excluded because it doesn't comprehensively cover PD, and several national guidelines derived from these four were excluded for overlap. This scope is defensible but means the review reflects the same evidence base repackaged by different groups, not genuinely independent assessments.
Red Flags
No formal conflict of interest disclosure for any author, which is notable for a paper touching on treatment controversies with industry-tied therapies (collagenase in particular)
"Inferred from contextual discussion" is not a rigorous abstraction method—classification errors are possible and not independently validated
The underlying evidence base the authors describe is itself weak: most treatment recommendations across all four guidelines rest on expert consensus, not RCTs
The Peyronie's Disease Questionnaire (PDQ), the primary patient-reported outcome tool endorsed across guidelines, is explicitly noted as inadequate for patients outside heterosexual partnerships or not engaging in penetrative sex—a significant construct validity gap
No quantitative synthesis; the paper describes what guidelines say but cannot adjudicate which is correct
Strengths
Covers all four major international guideline-issuing bodies in a structured, parallel format
Clearly identifies where divergence stems from regulatory differences (EU collagenase ban) versus genuine scientific disagreement versus evidence heterogeneity—a useful distinction
Flags the practical clinical consequence of guideline divergence: patients with identical disease presentations may receive substantially different treatments depending on geography and which guideline their clinician follows
Raises legitimate future-direction points: standardised outcome measurement, 3D photography for curvature assessment, and instruments validated for non-heterosexual or non-penetrative populations
Verdict
This paper is a useful map of where four major urology societies stand on Peyronie's disease, and its value is mostly cartographic. It confirms that the field is evidence-poor and guideline-heavy, that geographic and regulatory factors drive meaningful treatment variation, and that "expert consensus" is doing a lot of heavy lifting. It does not resolve any of the disagreements it documents—it can't, because the underlying trials don't exist yet. For clinicians navigating PD management, the structured comparison tables are the practical take-home. For researchers, the message is that almost every non-surgical treatment recommendation is a target for a properly powered RCT.